Rpo LLC Makes New $47,000 Investment in Precigen, Inc. (NASDAQ:PGEN)

Rpo LLC acquired a new stake in shares of Precigen, Inc. (NASDAQ:PGEN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 42,143 shares of the biotechnology company’s stock, valued at approximately $47,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after purchasing an additional 53,343 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in Precigen by 29.0% during the fourth quarter. CIBC Private Wealth Group LLC now owns 331,476 shares of the biotechnology company’s stock worth $391,000 after buying an additional 74,422 shares in the last quarter. Fore Capital LLC raised its position in Precigen by 27.7% in the 4th quarter. Fore Capital LLC now owns 391,811 shares of the biotechnology company’s stock valued at $439,000 after buying an additional 85,000 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Precigen by 4.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock valued at $1,432,000 after acquiring an additional 56,012 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Precigen by 7.3% during the 4th quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 13,338 shares during the last quarter. 33.51% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on PGEN. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Precigen in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.00.

Precigen Price Performance

Shares of PGEN opened at $1.48 on Thursday. The firm has a market cap of $435.18 million, a PE ratio of -2.69 and a beta of 1.58. Precigen, Inc. has a 1 year low of $0.65 and a 1 year high of $2.17. The stock’s fifty day moving average price is $1.69 and its two-hundred day moving average price is $1.19.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%. Sell-side analysts anticipate that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.